Becton, Dickinson and Company (BDX) Stock Price, News & Analysis

Company Overview

Becton, Dickinson and Company, commonly known as BD, is a leading global medical technology firm founded in 1897 by Maxwell Becton and Fairleigh Dickinson. Headquartered in Franklin Lakes, New Jersey, BD has evolved from a regional syringe manufacturer into a diversified supplier of medical devices, instrument systems and reagents. Over more than a century, the company has gained a reputation for quality and innovation, serving hospitals, clinical laboratories, life science researchers and pharmaceutical organizations worldwide.

BD’s operations are organized into three primary segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment delivers needles and syringes, infusion therapy and injection safety solutions designed to enhance patient comfort and reduce needlestick injuries. BD Life Sciences offers advanced diagnostic and research tools, including flow cytometry, molecular testing, microbiology systems and cellular analysis products. BD Interventional, strengthened by the 2017 acquisition of C.R. Bard, focuses on vascular access, oncology and surgical devices such as catheters, biopsy systems and drainage solutions.

With a presence in over 190 countries, BD operates manufacturing, distribution and research facilities across North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa. This expansive footprint enables the company to collaborate closely with healthcare providers and researchers, addressing regional challenges like infection prevention, chronic disease management and the rise of personalized medicine. BD’s global supply chain emphasizes rigorous quality assurance and regulatory compliance to ensure reliable product availability.

Under the leadership of President and Chief Executive Officer Thomas Polen, who assumed the role in February 2020, BD continues to invest significantly in research and development. Supported by an experienced executive team and board of directors, the company pursues innovations in digital health, advanced diagnostics and minimally invasive therapies. Through strategic partnerships, targeted acquisitions and internal development, BD aims to drive sustainable growth while advancing healthcare delivery and patient safety around the globe.

Key Stats

• Today's Range: $175.93 to $178.30
• 50-Day Range: $165.13 to $206.89
• 52-Week Range: $163.33 to $251.99
• Volume: 1.06 million shs
• Average Volume: 2.06 million shs
• Market Capitalization: $50.49 billion
• P/E Ratio: 33.62
• Dividend Yield: 2.36%
• Price Target: $219.22
• Consensus Rating: Hold

Becton, Dickinson and Company Stock Analysis - MarketRank™

Becton, Dickinson and Company scored higher than 97% of companies evaluated by MarketBeat, and ranked 166th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Becton, Dickinson and Company has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 4 buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Becton, Dickinson and Company has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 8.39%

Earnings Growth

Earnings for Becton, Dickinson and Company are expected to grow by 8.39% in the coming year, from $14.43 to $15.64 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Becton, Dickinson and Company is 33.62, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.55.

Price to Earnings Ratio vs. Sector

The P/E ratio of Becton, Dickinson and Company is 33.62, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.52.

Price to Earnings Growth Ratio

Becton, Dickinson and Company has a PEG Ratio of 1.33. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Becton, Dickinson and Company has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.12% of the float of Becton, Dickinson and Company has been sold short.

Short Interest Ratio / Days to Cover

Becton, Dickinson and Company has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Becton, Dickinson and Company has recently increased by 1.90%, indicating that investor sentiment is decreasing.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Becton, Dickinson and Company pays a meaningful dividend of 2.36%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Becton, Dickinson and Company has been increasing its dividend for 53 years.

Dividend Coverage

The dividend payout ratio of Becton, Dickinson and Company is 79.39%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Becton, Dickinson and Company will have a dividend payout ratio of 26.60% next year. This indicates that Becton, Dickinson and Company will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.48

Percentage of Shares Shorted

1.12% of the float of Becton, Dickinson and Company has been sold short.

Short Interest Ratio / Days to Cover

Becton, Dickinson and Company has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Becton, Dickinson and Company has recently increased by 1.90%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.31

News Sentiment

Becton, Dickinson and Company has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Becton, Dickinson and Company this week, compared to 23 articles on an average week.

Search Interest

18 people have searched for BDX on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.

MarketBeat Follows

Only 9 people have added Becton, Dickinson and Company to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Becton, Dickinson and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $294,105.00 in company stock.

Percentage Held by Insiders

Only 0.36% of the stock of Becton, Dickinson and Company is held by insiders.

Percentage Held by Institutions

86.97% of the stock of Becton, Dickinson and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BDX Stock Analysis - Frequently Asked Questions

How have BDX shares performed this year?

Becton, Dickinson and Company's stock was trading at $226.87 at the beginning of 2025. Since then, BDX stock has decreased by 22.4% and is now trading at $176.16.

How were Becton, Dickinson and Company's earnings last quarter?

Becton, Dickinson and Company (NYSE:BDX) issued its quarterly earnings data on Thursday, May, 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company's quarterly revenue was up 4.5% compared to the same quarter last year.
Read the conference call transcript.

How will Becton, Dickinson and Company's stock buyback program work?

Becton, Dickinson and Company's board initiated a share buyback plan on Tuesday, January 28th 2025, which permits the company to repurchase 10,000,000 outstanding shares, according to EventVestor. This permits the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company's leadership believes its stock is undervalued.

Does Becton, Dickinson and Company have any subsidiaries?

The following companies are subsidiaries of Becton, Dickinson and Company: Cytognos, Scanwell Health Inc., Tissuemed Ltd., Venclose Inc., Tepha Inc., Velano Vascular, GSL Solutions, and more.

Who are Becton, Dickinson and Company's major shareholders?

Top institutional investors of Becton, Dickinson and Company include Cacti Asset Management LLC (0.06%), Confluence Investment Management LLC (0.03%), Park National Corp OH (0.01%) and Jacobs & Co. CA (0.01%). Insiders that own company stock include Bertram L Scott, Thomas E Polen Jr, Claire Fraser, Shana Carol Neal, Roland Goette, Jeffrey William Henderson, Richard Byrd, Richard Byrd, Samrat S Khichi, Michael David Garrison, David Shan, David Hickey and Thomas J Spoerel.
View institutional ownership trends.

How do I buy shares of Becton, Dickinson and Company?

Shares of BDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Becton, Dickinson and Company own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Becton, Dickinson and Company investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Exxon Mobil (XOM), Broadcom (AVGO), AbbVie (ABBV) and Chevron (CVX).

Company Calendar

• Last Earnings: 5/01/2025
• Record date for 6/30 Dividend: 6/09/2025
• Ex-Dividend for 6/30 Dividend: 6/09/2025
• Dividend Payable: 6/30/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:BDX
• CIK: 10795
• Web: www.bd.com
• Phone: (201) 847-6800
• Fax: 201-847-6475
• Employees: 74,000
• Year Founded: 1897

Price Target and Rating

• Average Stock Price Target: $219.22
• High Stock Price Target: $290.00
• Low Stock Price Target: $185.00
• Potential Upside/Downside: +24.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.36
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.24
• Trailing P/E Ratio: 33.62
• Forward P/E Ratio: 12.21
• P/E Growth: 1.33
• Net Income: $1.71 billion
• Net Margins: 7.28%
• Pretax Margin: 8.06%
• Return on Equity: 15.99%
• Return on Assets: 7.36%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 1.13
• Quick Ratio: 0.64

Sales & Book Value

• Annual Sales: $20.18 billion
• Price / Sales: 2.50
• Cash Flow: $21.15 per share
• Price / Cash Flow: 8.33
• Book Value: $89.57 per share
• Price / Book: 1.97

Miscellaneous

• Outstanding Shares: 286,610,000
• Free Float: 285,575,000
• Market Cap: $50.49 billion
• Optionable: Optionable
• Beta: 0.25